Table 5. M-TEER registries.
| TRAMI | Zürich | GRASP | Hamburg | Mainz | Italy/Spain | Munich | Summary | |
|---|---|---|---|---|---|---|---|---|
| Publication | EuroIntervention 2017121 | EuroIntervention 2016122 | EHJ CVI 2014105 | EuroIntervention 2017123 | Clin Res Cardiol 2021124 | Eur J Heart Fail 2022125 | Unpublished | |
| No of patients | 766 pts | 119 pts | 146 pts | 139 pts | 606 pts | 503 pts | 602 pts | 2,881 pts |
| TR ≥3+ | 106/766 | 26/119 | - | 11/139 | 129/560 | 137/503 | 99/602 | 18.9% (508/2,689) |
| TR ≥2+ | 432/766 | 66/119 | 47/146 | 81/139 | 319/560 | 344/503 | 306/602 | 56.3% (1,595/2,835) |
|
TR ≥2+ at FU |
- | 35/67 | 16/143 | 52/133 | 191/426 | 287/503 | 135/331 | 44.7% (716/1,603) |
| Selection of European M-TEER (mitral valve transcatheter edge-to-edge repair) registries. In total, 2,881 patients (pts) were reported. Tricuspid regurgitation (TR) was evaluated before M-TEER in 2,835 patients and 56.3% of patients demonstrated moderate TR ≥2+. Severe TR ≥3+ was reported in 18.6% of cases (508 of 2,689 patients). After M-TEER, the rate of TR ≥2+ was reduced from 56.3% to 44.7%. FU: follow-up; No: number; Ref: reference | ||||||||